nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A3—Progesterone—uterine cancer	0.341	0.463	CbGbCtD
Amphetamine—SLC22A5—Dactinomycin—uterine cancer	0.168	0.228	CbGbCtD
Amphetamine—CYP2A6—Progesterone—uterine cancer	0.161	0.219	CbGbCtD
Amphetamine—CYP2D6—Progesterone—uterine cancer	0.0506	0.0688	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—uterine cancer	0.0155	0.021	CbGbCtD
Amphetamine—TAAR1—female reproductive system—uterine cancer	0.00498	0.0755	CbGeAlD
Amphetamine—CARTPT—female reproductive system—uterine cancer	0.00498	0.0755	CbGeAlD
Amphetamine—CARTPT—lymph node—uterine cancer	0.00292	0.0442	CbGeAlD
Amphetamine—Speech disorder—Medroxyprogesterone Acetate—uterine cancer	0.00261	0.0144	CcSEcCtD
Amphetamine—Blood pressure increased—Progesterone—uterine cancer	0.00248	0.0136	CcSEcCtD
Amphetamine—Dysmenorrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.0136	CcSEcCtD
Amphetamine—SLC18A2—uterine cervix—uterine cancer	0.00226	0.0343	CbGeAlD
Amphetamine—Blood pressure increased—Medroxyprogesterone Acetate—uterine cancer	0.00225	0.0124	CcSEcCtD
Amphetamine—Lightheadedness—Progesterone—uterine cancer	0.00222	0.0122	CcSEcCtD
Amphetamine—SLC22A3—myometrium—uterine cancer	0.00207	0.0313	CbGeAlD
Amphetamine—SLC18A2—endometrium—uterine cancer	0.00204	0.031	CbGeAlD
Amphetamine—Injury—Progesterone—uterine cancer	0.00196	0.0108	CcSEcCtD
Amphetamine—Libido decreased—Progesterone—uterine cancer	0.00194	0.0107	CcSEcCtD
Amphetamine—Euphoric mood—Medroxyprogesterone Acetate—uterine cancer	0.00193	0.0106	CcSEcCtD
Amphetamine—MAOB—myometrium—uterine cancer	0.00191	0.029	CbGeAlD
Amphetamine—SLC18A2—uterus—uterine cancer	0.00188	0.0285	CbGeAlD
Amphetamine—Disturbance in sexual arousal—Progesterone—uterine cancer	0.00179	0.00982	CcSEcCtD
Amphetamine—Affect lability—Progesterone—uterine cancer	0.00177	0.00975	CcSEcCtD
Amphetamine—Libido decreased—Medroxyprogesterone Acetate—uterine cancer	0.00176	0.00968	CcSEcCtD
Amphetamine—Irritability—Progesterone—uterine cancer	0.00172	0.00945	CcSEcCtD
Amphetamine—Mood swings—Progesterone—uterine cancer	0.00171	0.00938	CcSEcCtD
Amphetamine—SLC18A2—female reproductive system—uterine cancer	0.00169	0.0257	CbGeAlD
Amphetamine—Infection—Carboplatin—uterine cancer	0.00167	0.0092	CcSEcCtD
Amphetamine—Cerebrovascular accident—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.00916	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—STAR—uterine cancer	0.00164	0.102	CbGpPWpGaD
Amphetamine—Disturbance in sexual arousal—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.0089	CcSEcCtD
Amphetamine—SLC22A3—uterine cervix—uterine cancer	0.00161	0.0244	CbGeAlD
Amphetamine—Affect lability—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00883	CcSEcCtD
Amphetamine—Psychotic disorder—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00876	CcSEcCtD
Amphetamine—SLC22A3—smooth muscle tissue—uterine cancer	0.00156	0.0237	CbGeAlD
Amphetamine—Irritability—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.00856	CcSEcCtD
Amphetamine—Mood swings—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.0085	CcSEcCtD
Amphetamine—SLC18A2—vagina—uterine cancer	0.00153	0.0232	CbGeAlD
Amphetamine—SLC22A3—renal system—uterine cancer	0.00151	0.0228	CbGeAlD
Amphetamine—SLC22A5—myometrium—uterine cancer	0.0015	0.0228	CbGeAlD
Amphetamine—MAOB—uterine cervix—uterine cancer	0.00149	0.0226	CbGeAlD
Amphetamine—SLC22A3—endometrium—uterine cancer	0.00146	0.0221	CbGeAlD
Amphetamine—MAOB—decidua—uterine cancer	0.00142	0.0215	CbGeAlD
Amphetamine—SLC22A3—mammalian vulva—uterine cancer	0.00141	0.0213	CbGeAlD
Amphetamine—Weight decreased—Progesterone—uterine cancer	0.00141	0.00774	CcSEcCtD
Amphetamine—MAOB—renal system—uterine cancer	0.00139	0.0211	CbGeAlD
Amphetamine—Cardiomyopathy—Epirubicin—uterine cancer	0.00139	0.00764	CcSEcCtD
Amphetamine—Depression—Progesterone—uterine cancer	0.00138	0.00761	CcSEcCtD
Amphetamine—CYP2A6—vagina—uterine cancer	0.00137	0.0207	CbGeAlD
Amphetamine—Urinary tract infection—Progesterone—uterine cancer	0.00135	0.00742	CcSEcCtD
Amphetamine—MAOB—endometrium—uterine cancer	0.00135	0.0204	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—HNF1B—uterine cancer	0.00134	0.0832	CbGpPWpGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—CDKN1C—uterine cancer	0.00133	0.0831	CbGpPWpGaD
Amphetamine—Body temperature increased—Carboplatin—uterine cancer	0.00133	0.00732	CcSEcCtD
Amphetamine—SLC6A2—decidua—uterine cancer	0.00131	0.0199	CbGeAlD
Amphetamine—MAOB—mammalian vulva—uterine cancer	0.0013	0.0197	CbGeAlD
Amphetamine—Cardiomyopathy—Doxorubicin—uterine cancer	0.00129	0.00707	CcSEcCtD
Amphetamine—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.00128	0.00702	CcSEcCtD
Amphetamine—Depression—Medroxyprogesterone Acetate—uterine cancer	0.00125	0.00689	CcSEcCtD
Amphetamine—MAOB—uterus—uterine cancer	0.00124	0.0188	CbGeAlD
Amphetamine—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.00682	CcSEcCtD
Amphetamine—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.00123	0.00678	CcSEcCtD
Amphetamine—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.00672	CcSEcCtD
Amphetamine—SLC22A3—female reproductive system—uterine cancer	0.00121	0.0183	CbGeAlD
Amphetamine—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00663	CcSEcCtD
Amphetamine—Erythema multiforme—Progesterone—uterine cancer	0.00118	0.00648	CcSEcCtD
Amphetamine—SLC6A4—female reproductive system—uterine cancer	0.00117	0.0178	CbGeAlD
Amphetamine—SLC22A5—uterine cervix—uterine cancer	0.00117	0.0177	CbGeAlD
Amphetamine—Toxic epidermal necrolysis—Dactinomycin—uterine cancer	0.00115	0.0063	CcSEcCtD
Amphetamine—MAOB—female reproductive system—uterine cancer	0.00112	0.0169	CbGeAlD
Amphetamine—SLC22A3—female gonad—uterine cancer	0.0011	0.0166	CbGeAlD
Amphetamine—SLC22A5—renal system—uterine cancer	0.00109	0.0166	CbGeAlD
Amphetamine—SLC22A3—vagina—uterine cancer	0.00109	0.0165	CbGeAlD
Amphetamine—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.00587	CcSEcCtD
Amphetamine—Tension—Progesterone—uterine cancer	0.00106	0.00585	CcSEcCtD
Amphetamine—SLC22A5—endometrium—uterine cancer	0.00106	0.016	CbGeAlD
Amphetamine—Nervousness—Progesterone—uterine cancer	0.00105	0.00579	CcSEcCtD
Amphetamine—SLC6A2—female reproductive system—uterine cancer	0.00103	0.0157	CbGeAlD
Amphetamine—Tremor—Progesterone—uterine cancer	0.00102	0.00559	CcSEcCtD
Amphetamine—MAOB—female gonad—uterine cancer	0.00102	0.0154	CbGeAlD
Amphetamine—MAOB—vagina—uterine cancer	0.00101	0.0153	CbGeAlD
Amphetamine—SLC18A2—lymph node—uterine cancer	0.000991	0.015	CbGeAlD
Amphetamine—Angioedema—Progesterone—uterine cancer	0.000991	0.00545	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.000972	0.00535	CcSEcCtD
Amphetamine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.000964	0.0053	CcSEcCtD
Amphetamine—Palpitations—Progesterone—uterine cancer	0.000958	0.00527	CcSEcCtD
Amphetamine—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.000954	0.00525	CcSEcCtD
Amphetamine—Convulsion—Progesterone—uterine cancer	0.000939	0.00517	CcSEcCtD
Amphetamine—Hypertension—Progesterone—uterine cancer	0.000936	0.00515	CcSEcCtD
Amphetamine—Chest pain—Progesterone—uterine cancer	0.000923	0.00508	CcSEcCtD
Amphetamine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00092	0.00506	CcSEcCtD
Amphetamine—Anxiety—Progesterone—uterine cancer	0.00092	0.00506	CcSEcCtD
Amphetamine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000903	0.00497	CcSEcCtD
Amphetamine—Dry mouth—Progesterone—uterine cancer	0.000903	0.00496	CcSEcCtD
Amphetamine—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000898	0.00494	CcSEcCtD
Amphetamine—Anaphylactic shock—Progesterone—uterine cancer	0.000885	0.00487	CcSEcCtD
Amphetamine—Infection—Progesterone—uterine cancer	0.000879	0.00483	CcSEcCtD
Amphetamine—SLC22A5—female reproductive system—uterine cancer	0.000877	0.0133	CbGeAlD
Amphetamine—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.000868	0.00477	CcSEcCtD
Amphetamine—Tachycardia—Progesterone—uterine cancer	0.000864	0.00475	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—EZH2—uterine cancer	0.000857	0.0534	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Progesterone—uterine cancer	0.000855	0.0047	CcSEcCtD
Amphetamine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000851	0.00468	CcSEcCtD
Amphetamine—Anorexia—Progesterone—uterine cancer	0.000843	0.00464	CcSEcCtD
Amphetamine—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000836	0.0046	CcSEcCtD
Amphetamine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000833	0.00458	CcSEcCtD
Amphetamine—Erythema multiforme—Dactinomycin—uterine cancer	0.000832	0.00458	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000829	0.00456	CcSEcCtD
Amphetamine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000818	0.0045	CcSEcCtD
Amphetamine—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000802	0.00441	CcSEcCtD
Amphetamine—Insomnia—Progesterone—uterine cancer	0.0008	0.0044	CcSEcCtD
Amphetamine—SLC22A5—female gonad—uterine cancer	0.000798	0.0121	CbGeAlD
Amphetamine—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000797	0.00438	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—CDKN1C—uterine cancer	0.000795	0.0495	CbGpPWpGaD
Amphetamine—SLC22A5—vagina—uterine cancer	0.000793	0.012	CbGeAlD
Amphetamine—Dyspnoea—Progesterone—uterine cancer	0.000789	0.00434	CcSEcCtD
Amphetamine—Viral infection—Epirubicin—uterine cancer	0.000787	0.00433	CcSEcCtD
Amphetamine—Somnolence—Progesterone—uterine cancer	0.000787	0.00433	CcSEcCtD
Amphetamine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000783	0.0043	CcSEcCtD
Amphetamine—Dyspepsia—Progesterone—uterine cancer	0.000779	0.00428	CcSEcCtD
Amphetamine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000775	0.00426	CcSEcCtD
Amphetamine—Decreased appetite—Progesterone—uterine cancer	0.000769	0.00423	CcSEcCtD
Amphetamine—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000764	0.0042	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Progesterone—uterine cancer	0.000764	0.0042	CcSEcCtD
Amphetamine—Fatigue—Progesterone—uterine cancer	0.000763	0.0042	CcSEcCtD
Amphetamine—Dyskinesia—Epirubicin—uterine cancer	0.000757	0.00416	CcSEcCtD
Amphetamine—Constipation—Progesterone—uterine cancer	0.000757	0.00416	CcSEcCtD
Amphetamine—Viral infection—Doxorubicin—uterine cancer	0.000729	0.00401	CcSEcCtD
Amphetamine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000725	0.00399	CcSEcCtD
Amphetamine—Gastrointestinal pain—Progesterone—uterine cancer	0.000724	0.00398	CcSEcCtD
Amphetamine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000715	0.00393	CcSEcCtD
Amphetamine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000713	0.00392	CcSEcCtD
Amphetamine—CYP2D6—renal system—uterine cancer	0.000707	0.0107	CbGeAlD
Amphetamine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000706	0.00388	CcSEcCtD
Amphetamine—SLC22A3—lymph node—uterine cancer	0.000706	0.0107	CbGeAlD
Amphetamine—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000704	0.00387	CcSEcCtD
Amphetamine—Urticaria—Progesterone—uterine cancer	0.000703	0.00387	CcSEcCtD
Amphetamine—Dyskinesia—Doxorubicin—uterine cancer	0.0007	0.00385	CcSEcCtD
Amphetamine—Acute coronary syndrome—Etoposide—uterine cancer	0.0007	0.00385	CcSEcCtD
Amphetamine—Body temperature increased—Progesterone—uterine cancer	0.000699	0.00385	CcSEcCtD
Amphetamine—Abdominal pain—Progesterone—uterine cancer	0.000699	0.00385	CcSEcCtD
Amphetamine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000697	0.00383	CcSEcCtD
Amphetamine—Myocardial infarction—Etoposide—uterine cancer	0.000696	0.00383	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000692	0.00381	CcSEcCtD
Amphetamine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000691	0.0038	CcSEcCtD
Amphetamine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000686	0.00377	CcSEcCtD
Amphetamine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000656	0.00361	CcSEcCtD
Amphetamine—MAOB—lymph node—uterine cancer	0.000653	0.00989	CbGeAlD
Amphetamine—Hypersensitivity—Progesterone—uterine cancer	0.000652	0.00359	CcSEcCtD
Amphetamine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000637	0.0035	CcSEcCtD
Amphetamine—Asthenia—Progesterone—uterine cancer	0.000635	0.00349	CcSEcCtD
Amphetamine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000634	0.00349	CcSEcCtD
Amphetamine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000634	0.00349	CcSEcCtD
Amphetamine—Infection—Dactinomycin—uterine cancer	0.000621	0.00342	CcSEcCtD
Amphetamine—Diarrhoea—Progesterone—uterine cancer	0.000605	0.00333	CcSEcCtD
Amphetamine—SLC6A2—lymph node—uterine cancer	0.000605	0.00916	CbGeAlD
Amphetamine—Erythema multiforme—Etoposide—uterine cancer	0.000602	0.00331	CcSEcCtD
Amphetamine—Anorexia—Dactinomycin—uterine cancer	0.000596	0.00328	CcSEcCtD
Amphetamine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000591	0.00325	CcSEcCtD
Amphetamine—Dizziness—Progesterone—uterine cancer	0.000585	0.00322	CcSEcCtD
Amphetamine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000575	0.00316	CcSEcCtD
Amphetamine—CYP2D6—female reproductive system—uterine cancer	0.000566	0.00858	CbGeAlD
Amphetamine—Vomiting—Progesterone—uterine cancer	0.000563	0.00309	CcSEcCtD
Amphetamine—Rash—Progesterone—uterine cancer	0.000558	0.00307	CcSEcCtD
Amphetamine—Dermatitis—Progesterone—uterine cancer	0.000557	0.00307	CcSEcCtD
Amphetamine—Headache—Progesterone—uterine cancer	0.000554	0.00305	CcSEcCtD
Amphetamine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000549	0.00302	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—uterine cancer	0.000544	0.00299	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—uterine cancer	0.000539	0.00297	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.000536	0.0334	CbGpPWpGaD
Amphetamine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00053	0.00292	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—uterine cancer	0.000527	0.0029	CcSEcCtD
Amphetamine—Nausea—Progesterone—uterine cancer	0.000526	0.00289	CcSEcCtD
Amphetamine—CYP2D6—female gonad—uterine cancer	0.000515	0.0078	CbGeAlD
Amphetamine—SLC22A5—lymph node—uterine cancer	0.000513	0.00777	CbGeAlD
Amphetamine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000511	0.00281	CcSEcCtD
Amphetamine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00051	0.0028	CcSEcCtD
Amphetamine—Affect lability—Epirubicin—uterine cancer	0.000508	0.00279	CcSEcCtD
Amphetamine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000506	0.00278	CcSEcCtD
Amphetamine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000505	0.00278	CcSEcCtD
Amphetamine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000502	0.00276	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—uterine cancer	0.000494	0.00272	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—uterine cancer	0.000494	0.00272	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—uterine cancer	0.000489	0.00269	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000487	0.00268	CcSEcCtD
Amphetamine—Convulsion—Etoposide—uterine cancer	0.000481	0.00264	CcSEcCtD
Amphetamine—Hypertension—Etoposide—uterine cancer	0.000479	0.00263	CcSEcCtD
Amphetamine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000476	0.00262	CcSEcCtD
Amphetamine—Chest pain—Etoposide—uterine cancer	0.000472	0.0026	CcSEcCtD
Amphetamine—Abdominal pain upper—Epirubicin—uterine cancer	0.000471	0.00259	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—uterine cancer	0.00047	0.00259	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000465	0.00256	CcSEcCtD
Amphetamine—Hypersensitivity—Dactinomycin—uterine cancer	0.000461	0.00253	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—uterine cancer	0.000453	0.00249	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—uterine cancer	0.000452	0.00249	CcSEcCtD
Amphetamine—Infection—Etoposide—uterine cancer	0.00045	0.00247	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—uterine cancer	0.000449	0.00247	CcSEcCtD
Amphetamine—Tachycardia—Etoposide—uterine cancer	0.000442	0.00243	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—uterine cancer	0.000438	0.00241	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—uterine cancer	0.000436	0.0024	CcSEcCtD
Amphetamine—Anorexia—Etoposide—uterine cancer	0.000431	0.00237	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.00043	0.00237	CcSEcCtD
Amphetamine—Diarrhoea—Dactinomycin—uterine cancer	0.000428	0.00235	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—uterine cancer	0.000407	0.00224	CcSEcCtD
Amphetamine—Weight decreased—Epirubicin—uterine cancer	0.000404	0.00222	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—uterine cancer	0.000404	0.00222	CcSEcCtD
Amphetamine—Somnolence—Etoposide—uterine cancer	0.000402	0.00221	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—uterine cancer	0.000398	0.00219	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000394	0.00217	CcSEcCtD
Amphetamine—Rash—Dactinomycin—uterine cancer	0.000394	0.00217	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—uterine cancer	0.000393	0.00216	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000391	0.00215	CcSEcCtD
Amphetamine—Fatigue—Etoposide—uterine cancer	0.00039	0.00215	CcSEcCtD
Amphetamine—Constipation—Etoposide—uterine cancer	0.000387	0.00213	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—uterine cancer	0.000387	0.00213	CcSEcCtD
Amphetamine—Sweating—Epirubicin—uterine cancer	0.000381	0.0021	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000377	0.00207	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—uterine cancer	0.000373	0.00205	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—uterine cancer	0.000371	0.00204	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—uterine cancer	0.00037	0.00204	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000365	0.00201	CcSEcCtD
Amphetamine—Urticaria—Etoposide—uterine cancer	0.00036	0.00198	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—uterine cancer	0.000358	0.00197	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—uterine cancer	0.000358	0.00197	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—uterine cancer	0.000358	0.00197	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—uterine cancer	0.000353	0.00194	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—uterine cancer	0.000338	0.00186	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—uterine cancer	0.000333	0.00183	CcSEcCtD
Amphetamine—Asthenia—Etoposide—uterine cancer	0.000325	0.00179	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—uterine cancer	0.000312	0.00172	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—uterine cancer	0.00031	0.0017	CcSEcCtD
Amphetamine—MAOB—Tryptophan metabolism—CYP19A1—uterine cancer	0.000308	0.0192	CbGpPWpGaD
Amphetamine—Tension—Epirubicin—uterine cancer	0.000305	0.00168	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—uterine cancer	0.000302	0.00166	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—PTEN—uterine cancer	0.000302	0.0188	CbGpPWpGaD
Amphetamine—Dizziness—Etoposide—uterine cancer	0.000299	0.00165	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—RRM2—uterine cancer	0.000291	0.0181	CbGpPWpGaD
Amphetamine—Vomiting—Etoposide—uterine cancer	0.000288	0.00158	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—EP300—uterine cancer	0.000288	0.0179	CbGpPWpGaD
Amphetamine—Agitation—Epirubicin—uterine cancer	0.000286	0.00157	CcSEcCtD
Amphetamine—Rash—Etoposide—uterine cancer	0.000285	0.00157	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—uterine cancer	0.000285	0.00157	CcSEcCtD
Amphetamine—Headache—Etoposide—uterine cancer	0.000284	0.00156	CcSEcCtD
Amphetamine—Tension—Doxorubicin—uterine cancer	0.000282	0.00155	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—uterine cancer	0.000279	0.00154	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—uterine cancer	0.000275	0.00151	CcSEcCtD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000275	0.0171	CbGpPWpGaD
Amphetamine—Convulsion—Epirubicin—uterine cancer	0.000269	0.00148	CcSEcCtD
Amphetamine—Nausea—Etoposide—uterine cancer	0.000269	0.00148	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—uterine cancer	0.000268	0.00148	CcSEcCtD
Amphetamine—Chest pain—Epirubicin—uterine cancer	0.000265	0.00146	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—uterine cancer	0.000264	0.00145	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—uterine cancer	0.000264	0.00145	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—uterine cancer	0.000259	0.00142	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—uterine cancer	0.000254	0.0014	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—uterine cancer	0.000254	0.0014	CcSEcCtD
Amphetamine—Infection—Epirubicin—uterine cancer	0.000252	0.00139	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—uterine cancer	0.000249	0.00137	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—uterine cancer	0.000248	0.00137	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—uterine cancer	0.000248	0.00136	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—uterine cancer	0.000245	0.00135	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—uterine cancer	0.000245	0.00135	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—uterine cancer	0.000244	0.00134	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—uterine cancer	0.000242	0.00133	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—uterine cancer	0.00024	0.00132	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000235	0.00129	CcSEcCtD
Amphetamine—Infection—Doxorubicin—uterine cancer	0.000233	0.00128	CcSEcCtD
Amphetamine—Insomnia—Epirubicin—uterine cancer	0.000229	0.00126	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—uterine cancer	0.000229	0.00126	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000227	0.00125	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—uterine cancer	0.000226	0.00124	CcSEcCtD
Amphetamine—Somnolence—Epirubicin—uterine cancer	0.000226	0.00124	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—uterine cancer	0.000224	0.00123	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—uterine cancer	0.000223	0.00123	CcSEcCtD
Amphetamine—Decreased appetite—Epirubicin—uterine cancer	0.000221	0.00121	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000219	0.0012	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—uterine cancer	0.000219	0.0012	CcSEcCtD
Amphetamine—Constipation—Epirubicin—uterine cancer	0.000217	0.00119	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—uterine cancer	0.000212	0.00117	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—uterine cancer	0.000209	0.00115	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—uterine cancer	0.000209	0.00115	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000207	0.00114	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—uterine cancer	0.000207	0.00114	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—uterine cancer	0.000206	0.0128	CbGpPWpGaD
Amphetamine—Decreased appetite—Doxorubicin—uterine cancer	0.000204	0.00112	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000203	0.00111	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—uterine cancer	0.000202	0.00111	CcSEcCtD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000202	0.0126	CbGpPWpGaD
Amphetamine—Urticaria—Epirubicin—uterine cancer	0.000202	0.00111	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—uterine cancer	0.000201	0.0011	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—uterine cancer	0.000201	0.0011	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—uterine cancer	0.000201	0.0011	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000192	0.00106	CcSEcCtD
Amphetamine—Hypersensitivity—Epirubicin—uterine cancer	0.000187	0.00103	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—uterine cancer	0.000186	0.00103	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—uterine cancer	0.000186	0.00102	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—uterine cancer	0.000186	0.00102	CcSEcCtD
Amphetamine—Asthenia—Epirubicin—uterine cancer	0.000182	0.001	CcSEcCtD
Amphetamine—Diarrhoea—Epirubicin—uterine cancer	0.000174	0.000955	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—uterine cancer	0.000173	0.000951	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—uterine cancer	0.000168	0.000926	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—uterine cancer	0.000168	0.000923	CcSEcCtD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000165	0.0103	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—STAR—uterine cancer	0.000165	0.0103	CbGpPWpGaD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000163	0.0101	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—ABCC9—uterine cancer	0.000162	0.0101	CbGpPWpGaD
Amphetamine—Vomiting—Epirubicin—uterine cancer	0.000161	0.000887	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—uterine cancer	0.000161	0.000883	CcSEcCtD
Amphetamine—Rash—Epirubicin—uterine cancer	0.00016	0.00088	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—uterine cancer	0.00016	0.000879	CcSEcCtD
Amphetamine—Headache—Epirubicin—uterine cancer	0.000159	0.000874	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—uterine cancer	0.000155	0.000854	CcSEcCtD
Amphetamine—Nausea—Epirubicin—uterine cancer	0.000151	0.000829	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—uterine cancer	0.000149	0.000821	CcSEcCtD
Amphetamine—Rash—Doxorubicin—uterine cancer	0.000148	0.000814	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—uterine cancer	0.000148	0.000813	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.000147	0.00917	CbGpPWpGaD
Amphetamine—Headache—Doxorubicin—uterine cancer	0.000147	0.000809	CcSEcCtD
Amphetamine—MAOB—Biological oxidations—CYP11A1—uterine cancer	0.000146	0.00909	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—NFE2L2—uterine cancer	0.000144	0.00895	CbGpPWpGaD
Amphetamine—Nausea—Doxorubicin—uterine cancer	0.000139	0.000767	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—GPX3—uterine cancer	0.000137	0.00854	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—HNF1B—uterine cancer	0.000134	0.00837	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000134	0.00833	CbGpPWpGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.000132	0.00822	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—NFE2L2—uterine cancer	0.000124	0.0077	CbGpPWpGaD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000121	0.00756	CbGpPWpGaD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00012	0.00746	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GPX3—uterine cancer	0.000118	0.00735	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—NFE2L2—uterine cancer	0.00011	0.00682	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—CYP19A1—uterine cancer	0.000107	0.00669	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000106	0.0066	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GPX3—uterine cancer	0.000104	0.00651	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—STAR—uterine cancer	0.000101	0.00628	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.84e-05	0.00613	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—ESR2—uterine cancer	9.79e-05	0.00609	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—ABCC9—uterine cancer	9.66e-05	0.00602	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.26e-05	0.00576	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—NFE2L2—uterine cancer	9.15e-05	0.0057	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.13e-05	0.00569	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GPX3—uterine cancer	8.73e-05	0.00544	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	8.71e-05	0.00543	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—EZH2—uterine cancer	8.62e-05	0.00537	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—HNF1B—uterine cancer	8.22e-05	0.00512	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	7.85e-05	0.00489	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.53e-05	0.00469	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKR1B10—uterine cancer	7.53e-05	0.00469	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.51e-05	0.00468	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.5e-05	0.00467	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—CYP11A1—uterine cancer	7.11e-05	0.00443	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	7.07e-05	0.0044	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.81e-05	0.00424	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.72e-05	0.00419	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	6.57e-05	0.00409	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RNF43—uterine cancer	6.24e-05	0.00389	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	6.21e-05	0.00387	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CCL2—uterine cancer	5.98e-05	0.00372	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.86e-05	0.00365	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NDUFB11—uterine cancer	5.77e-05	0.00359	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SRD5A2—uterine cancer	5.77e-05	0.00359	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INHBA—uterine cancer	5.71e-05	0.00356	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—uterine cancer	5.59e-05	0.00348	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.52e-05	0.00344	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—EZH2—uterine cancer	5.27e-05	0.00328	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—CYP19A1—uterine cancer	5.23e-05	0.00326	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.19e-05	0.00323	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKR1C1—uterine cancer	5.14e-05	0.0032	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NDUFB11—uterine cancer	4.88e-05	0.00304	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SRD5A2—uterine cancer	4.88e-05	0.00304	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	4.82e-05	0.003	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—uterine cancer	4.73e-05	0.00294	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	4.23e-05	0.00264	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—STAR—uterine cancer	4.17e-05	0.0026	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKR1B1—uterine cancer	4.17e-05	0.0026	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—uterine cancer	4.13e-05	0.00257	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	3.99e-05	0.00248	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKR1C3—uterine cancer	3.96e-05	0.00246	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	3.93e-05	0.00245	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PGR—uterine cancer	3.86e-05	0.0024	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	3.81e-05	0.00237	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	3.71e-05	0.00231	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—YWHAE—uterine cancer	3.68e-05	0.00229	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—EP300—uterine cancer	3.54e-05	0.00221	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKR1B1—uterine cancer	3.53e-05	0.0022	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—STAR—uterine cancer	3.53e-05	0.0022	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FBXW7—uterine cancer	3.53e-05	0.0022	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—uterine cancer	3.36e-05	0.00209	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—POLD1—uterine cancer	3.27e-05	0.00204	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STK11—uterine cancer	3.08e-05	0.00192	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CCL2—uterine cancer	3.07e-05	0.00191	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKR1C1—uterine cancer	3.06e-05	0.00191	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PTEN—uterine cancer	3.03e-05	0.00189	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.93e-05	0.00183	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—EP300—uterine cancer	2.89e-05	0.0018	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.89e-05	0.0018	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SOCS3—uterine cancer	2.89e-05	0.0018	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SRD5A2—uterine cancer	2.81e-05	0.00175	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NDUFB11—uterine cancer	2.81e-05	0.00175	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—POLD1—uterine cancer	2.77e-05	0.00172	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN2B—uterine cancer	2.76e-05	0.00172	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—RRM2—uterine cancer	2.73e-05	0.0017	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1R—uterine cancer	2.68e-05	0.00167	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—uterine cancer	2.67e-05	0.00166	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—DCN—uterine cancer	2.65e-05	0.00165	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKR1C1—uterine cancer	2.59e-05	0.00161	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—uterine cancer	2.54e-05	0.00158	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMAD3—uterine cancer	2.52e-05	0.00157	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP11A1—uterine cancer	2.5e-05	0.00155	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—uterine cancer	2.43e-05	0.00151	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGFR2—uterine cancer	2.41e-05	0.0015	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKR1C3—uterine cancer	2.36e-05	0.00147	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—RRM2—uterine cancer	2.31e-05	0.00144	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—DCN—uterine cancer	2.24e-05	0.0014	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP11A1—uterine cancer	2.11e-05	0.00131	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—uterine cancer	2.07e-05	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ESR1—uterine cancer	2.06e-05	0.00128	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKR1B1—uterine cancer	2.03e-05	0.00127	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—STAR—uterine cancer	2.03e-05	0.00127	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKR1C3—uterine cancer	1.99e-05	0.00124	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NRAS—uterine cancer	1.95e-05	0.00121	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—uterine cancer	1.95e-05	0.00121	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PTEN—uterine cancer	1.86e-05	0.00116	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP19A1—uterine cancer	1.84e-05	0.00114	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—STK11—uterine cancer	1.84e-05	0.00114	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	1.83e-05	0.00114	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—uterine cancer	1.82e-05	0.00113	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL2—uterine cancer	1.81e-05	0.00113	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—EP300—uterine cancer	1.77e-05	0.0011	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKR1B10—uterine cancer	1.76e-05	0.00109	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CA—uterine cancer	1.69e-05	0.00106	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—uterine cancer	1.68e-05	0.00104	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—POLD1—uterine cancer	1.59e-05	0.000993	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.58e-05	0.000981	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.58e-05	0.000981	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP19A1—uterine cancer	1.55e-05	0.000967	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—STK11—uterine cancer	1.55e-05	0.000967	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CA—uterine cancer	1.54e-05	0.000958	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—uterine cancer	1.51e-05	0.000943	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—uterine cancer	1.51e-05	0.000941	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKR1C1—uterine cancer	1.49e-05	0.000929	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RNF43—uterine cancer	1.46e-05	0.000907	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.45e-05	0.000902	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—uterine cancer	1.43e-05	0.000893	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—uterine cancer	1.42e-05	0.000887	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1B—uterine cancer	1.4e-05	0.000872	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL2—uterine cancer	1.39e-05	0.000868	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—uterine cancer	1.38e-05	0.000862	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—uterine cancer	1.38e-05	0.000859	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INHBA—uterine cancer	1.33e-05	0.000829	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—RRM2—uterine cancer	1.33e-05	0.000828	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CTNNB1—uterine cancer	1.32e-05	0.000823	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—DCN—uterine cancer	1.29e-05	0.000804	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—uterine cancer	1.29e-05	0.000803	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—uterine cancer	1.27e-05	0.000789	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—uterine cancer	1.26e-05	0.000783	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—uterine cancer	1.23e-05	0.000765	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP11A1—uterine cancer	1.22e-05	0.000757	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKR1C1—uterine cancer	1.2e-05	0.000747	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—uterine cancer	1.17e-05	0.000727	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—uterine cancer	1.16e-05	0.000725	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—uterine cancer	1.16e-05	0.000723	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—uterine cancer	1.15e-05	0.000716	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKR1C3—uterine cancer	1.15e-05	0.000715	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.14e-05	0.00071	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—STAR—uterine cancer	1.14e-05	0.00071	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—uterine cancer	1.1e-05	0.000687	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—uterine cancer	9.89e-06	0.000616	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKR1C3—uterine cancer	9.23e-06	0.000575	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—uterine cancer	9.09e-06	0.000566	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PGR—uterine cancer	8.99e-06	0.00056	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—STK11—uterine cancer	8.94e-06	0.000557	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP19A1—uterine cancer	8.94e-06	0.000557	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—POLD1—uterine cancer	8.94e-06	0.000557	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—uterine cancer	8.79e-06	0.000548	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—YWHAE—uterine cancer	8.58e-06	0.000534	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—uterine cancer	8.41e-06	0.000524	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKR1C1—uterine cancer	8.36e-06	0.000521	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FBXW7—uterine cancer	8.22e-06	0.000512	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—uterine cancer	7.67e-06	0.000478	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—RRM2—uterine cancer	7.45e-06	0.000464	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—uterine cancer	7.43e-06	0.000463	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—uterine cancer	7.32e-06	0.000456	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DCN—uterine cancer	7.24e-06	0.000451	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STK11—uterine cancer	7.19e-06	0.000448	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL2—uterine cancer	7.16e-06	0.000446	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.82e-06	0.000425	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SOCS3—uterine cancer	6.73e-06	0.000419	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—uterine cancer	6.72e-06	0.000419	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—uterine cancer	6.49e-06	0.000404	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—uterine cancer	6.44e-06	0.000401	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKR1C3—uterine cancer	6.44e-06	0.000401	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—uterine cancer	6.26e-06	0.00039	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—uterine cancer	6.23e-06	0.000388	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—uterine cancer	6.19e-06	0.000386	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMAD3—uterine cancer	5.88e-06	0.000366	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—uterine cancer	5.66e-06	0.000352	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGFR2—uterine cancer	5.61e-06	0.00035	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—uterine cancer	5.41e-06	0.000337	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—STK11—uterine cancer	5.01e-06	0.000312	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP19A1—uterine cancer	5.01e-06	0.000312	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—uterine cancer	4.8e-06	0.000299	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—uterine cancer	4.58e-06	0.000285	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—uterine cancer	4.54e-06	0.000283	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—uterine cancer	4.42e-06	0.000275	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL2—uterine cancer	4.23e-06	0.000263	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—uterine cancer	3.95e-06	0.000246	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—uterine cancer	3.91e-06	0.000243	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—uterine cancer	3.77e-06	0.000235	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—uterine cancer	3.74e-06	0.000233	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—uterine cancer	3.74e-06	0.000233	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	3.59e-06	0.000224	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—uterine cancer	3.57e-06	0.000222	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—uterine cancer	3.52e-06	0.00022	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—uterine cancer	3.34e-06	0.000208	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—uterine cancer	3.32e-06	0.000207	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—uterine cancer	3.26e-06	0.000203	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—uterine cancer	3.23e-06	0.000201	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNB1—uterine cancer	3.08e-06	0.000192	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—uterine cancer	3.01e-06	0.000187	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—uterine cancer	2.93e-06	0.000183	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—uterine cancer	2.87e-06	0.000179	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—uterine cancer	2.71e-06	0.000169	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—uterine cancer	2.68e-06	0.000167	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—uterine cancer	2.64e-06	0.000164	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—uterine cancer	2.31e-06	0.000144	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—uterine cancer	2.15e-06	0.000134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—uterine cancer	2.12e-06	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—uterine cancer	2.1e-06	0.000131	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—uterine cancer	2.05e-06	0.000128	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—uterine cancer	2e-06	0.000125	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—uterine cancer	1.96e-06	0.000122	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—uterine cancer	1.73e-06	0.000108	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.48e-06	9.21e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—uterine cancer	1.21e-06	7.53e-05	CbGpPWpGaD
